AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1655080> since 2018-10-29T17:05:05Z

Published version:

DOI:10.1080/17425255.2018.1416093

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

"Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?"

Abstract

Introduction

WHO global strategy is to end TB epidemic by 2035. Pharmacokinetic and pharmacogenetic studies are widely spreading and might confirm their potential role in optimizing treatment outcome in specific settings. Insufficient drug exposure seems to be a relevant factor for tuberculosis outcome and for the risk of emergence of phenotypic resistance.

Areas Covered

This review will report available pharmacokinetic and pharmacogenetic data of first and second-line antituberculars relating to efficacy and toxicity. Pharmacodynamic implications of optimized drugs are discussed. A specific session describes innovative investigations on drug penetration in lesions.

Expert Opinion

The optimal use of available antitubercular drugs is paramount for tuberculosis control and eradication. Waiting for the results of ongoing trials higher RIF doses should be reserved to those with tubercular meningitis. TDM using limiting sampling strategies, is suggested in patients at risk of failure and in those subjects with slow response to treatment. Further studies are needed in order to provide definitive recommendations of pharmacogenetic-based individualization: however lower INH doses in *NAT2* slow acetylators and higher RIF doses in those presenting *SLCO1B1* loss of function genes are promising strategies. Data on tissue drug penetration are needed as well as pharmacological modelling in order to inform tailored strategies.

Keywords: Tuberculosis, *SLCO1B1*, high-dose rifampicin, lesion penetration, therapeutic drug monitoring, acetylator status.

Abbreviations: RIF, rifampicin, RFB, rifabutin; RPT, rifapentine; INH, isoniazid; ETB, ethambutol; PZA, pyrazinamide; AUC Area Under the Curve; PK, pharmacokinetics; PD, pharmacodynamics; C_{max} maximal concentration, TDM, Therapeutic Drug Monitoring.

Article highlights

- Inter- and intraindividual variability in the pharmacokinetics of antitubercular agents might be involved in explaining high variability of response, the likelihood of drugs' underexposure, the high prevalence of drug-related toxicity and the selection of multi-resistant strains.
- Actual rifampicin dose is suboptimal and trials investigating increased dose are ongoing. Potential effect of pyrazinamide in shortening treatment duration due to its great sterilizing activity is encouraging in designing new regimens after the failure of trials with fluoroquinolones.
- Pharmacogenetic studies observed an association between *SLCO1B1* genetic polymorphism (rs4149032) and reduced rifampicin concentrations. A *NAT2*-guided trial reported less isoniazid related liver injury and treatment failures.
- Drugs penetration in lesions and intracellular may contribute to treatment outcome for the relation with incidence of relapse or the development of phenotypic drug resistance.
- New regimens with new and optimized drugs are dramatically needed focusing on safety, efficacy and PK/PD characteristics of drugs; research on pharmacokinetics in special populations are warranted to better define individualized treatment approach.

1. Introduction

Tuberculosis (TB) with 9.6 million new cases is a worldwide leading infection and is responsible for approximately 1.5 million deaths in 2014[1].

1 The goal of reversing TB epidemic has been reached by 2015; currently, WHO has built up a
2 strategy to end the global epidemic by 2035 with targets to reduce TB deaths by 95%, cut new cases
3 by 90% between 2015 and 2035, and to ensure that no family is burdened with catastrophic costs
4 due to TB[2].

5 Combining several antitubercular drugs (ATDs) is a milestone in TB treatment[3].

6 This approach is due to the hypothesis of existing bacterial subpopulations with different drug
7 susceptibility: a first subpopulation of extracellular and rapidly dividing mycobacteria early killed
8 by therapy, a second subpopulation with an intermediate grade of replication residing in
9 fagolysosomes and, possibly, a third subpopulation consisted of dormant and persister mycobacteria
10 in monocyte-macrophagic cells and in caseum lesions[4]. Conversely, a second hypothesis
11 considers this latter population having the same drug susceptibility as the others and being the cause
12 of persistent disease, due to the fact that the mycobacteria are here sequestered in thick-walled
13 granuloma where ATDs hardly penetrate.

14

15 Therefore the activity of a multidrug regimen with specific characteristics of each component
16 ensures a fast bactericidal effect followed by a sterilizing effect to prevent relapse and selection of
17 drug resistance. Although the current TB regimen is effective with 95% of cure rate (in drug
18 susceptible TB under optimal condition), there are still many undefined issues such as the high
19 variability of response, the likelihood of drugs underexposure, the high prevalence of drug-related
20 toxicity and the selection of multi-resistant strains. The lack of early biomarkers for predicting
21 treatment efficacy, cure and identification of patients requiring prolonged treatment increased
22 complexity to this challenging subject[5]. Moreover the current pipeline is insufficient to tackle the
23 emergent issue of MDR/XDR TB (multidrug-resistant and extensively-drug resistant TB) issue[6].

24 After 40 years of no ATDs development, bedaquiline and delamanid have received accelerated
25 regulatory approval bringing some advance in treatment of resistant strains and some other
26 compounds are under study.

1 Interindividual variability in the pharmacokinetics (PK) of ATDs might be involved in explaining
2 such variability and has been identified as a key factor for the sterilizing effect and for the selection
3 of phenotypic resistance. Low maximum plasma concentrations have been associated with treatment
4 failure, relapse and acquired drug resistance regardless of HIV status; dose-adjustments after drug
5 monitoring has been related to better clinical outcomes[7,8]. Pharmacogenetics (PG) is the study of
6 interindividual variation in DNA sequences related to drug metabolic pathways. Inter-individual
7 variability, tissue penetration and drug-to-drug interactions are partially explained by genetic
8 variants in gene encoding for metabolizing or transporting proteins: knowing patients' genetic asset
9 may pave the way to tailored treatment.

10 Repurposing existing drugs and exploring new regimens, different doses, dosing schedules and
11 route of administration seem a productive tool to possibly shorten treatment in drug susceptible and
12 improve outcome in MDR tuberculosis.[9] Preliminary studies and evidence in selected
13 extrapulmonary disease point out that higher rifampicin (RIF) doses may be safe and increase
14 treatment efficacy[10].

15 Aim of the following review is to provide an insight in clinical pharmacokinetics and
16 pharmacogenetics of ATDs and to discuss warranted studies in this field.

19 **2.1 Methods**

20 Articles cited in this review were obtained through searches of the electronic database MEDLINE
21 up to 15th December 2016, meeting abstract databases and reference lists from key reviews. Search
22 terms included "tuberculosis", "antitubercular", "pharmacokinetics", "pharmacogenetics" and
23 "SNPs". Priority was given to primary research publications. The search was limited to English, but
24 was not restricted by date.

25 **2.2 Combination of antitubercular treatment**

1
2 International guidelines recommend for drug-susceptible TB the association of RIF, isoniazid
3 (INH), ethambutol (ETB) and pyrazinamide (PZA) for two months followed by four months of RIF
4 and INH.

5 For MDR treatment anti-TB drugs are grouped according to efficacy and drug class. New
6 regrouping has been published in the WHO's 2016 update . Group A are fluoroquinolones (FQ,
7 levofloxacin, moxifloxacin and gatifloxacin) and group B are injectable drugs (amikacin,
8 capreomycin, kanamycin). Other core second-line agents, in order of preference are
9 ethionamide/prothionamide, cycloserine/terizidone, linezolid and clofazimine. Add-on agents were
10 split in three different subgroups: D1 includes pyrazinamide, ethambutol and high-dose isoniazid
11 (15-20 mg/kg); D2 consists of bedaquiline and delamanid; D3 is made up of p-aminosalicylic acid
12 (PAS), imipenem-cilastatin, meropenem, clavulanate and thioacetazone[11].

13 Bedaquiline, delamanid and another new compound pretomanid (PA-824) are in clinical Phase 3
14 and when the results will be available these new drugs will be re-evaluated to design the core MDR-
15 TB regimen (STAND phase 3 trial testing the efficacy, safety and tolerability of moxifloxacin,
16 pretomanid and PZA is presently on clinical hold)[12]. In patients with RIF-resistant or multidrug-
17 resistant TB, a conventional regimen with at least five effective TB medicines during the intensive
18 phase is recommended, including PZA and one drug chosen from group A, one from group B and at
19 least two from group C ($PZA + A_1 + B_1 + C_2$); if the minimum number of effective drugs is not
20 reached an agent from group D2 and others from group D3 may be added to bring the total to five
21 active agents. An intensive phase of 8 months is suggested for most patients and the total duration
22 should be modified according to patients' response: new patients need to be treated for 20
23 months.[13] A shorter MDR-TB regimen (9-12 months) may be used in patients previously
24 untreated with second-line drugs without resistance to FQ and second line injectable agents:
25 detailed information can be found in WHO treatment guidelines for drug-resistant tuberculosis,
26 2016 update.[11]

2.3 Pharmacokinetics of ATDs and efficacy

Pharmacokinetic and pharmacodynamic (PD) properties of first, second-line and novel drugs are resumed in **Table 1, 2 and 3**. First-line anti tuberculars and FQ show concentration-dependent killing and have a long post antibiotic effect. AUC/MIC (where AUC is the area under the concentration-time curve of a drug) is the best PD parameter to predict the activity. For RIF, maximal concentration ($C_{\max}$) shows a good correlation with AUC and it is often used as a surrogate of the latter[14–16]. Gumbo *et al.* suggested that AUC/MIC is the PK/PD parameter most associated with bactericidal activity, while $C_{\max}$ /MIC is associated with the prevention of resistance selection[17].

Studies have highlighted the importance of ATDs concentrations on the rate of kill of *M. tuberculosis* in hollow fiber systems[17], animal models[18] and patients[19].

Few clinical studies have prospectively shown the association between plasma drug concentrations and outcome and results are heterogeneous. Pasipanodya[20] found that the three best predictors of poor long term outcome were: PZA 24-hour $AUC \leq 363$ mg*h/L, RIF $AUC \leq 13$ mg*h/L, and INH $AUC \leq 52$ mg*h/L. Moreover low RIF and INH $C_{\max}$ and AUC preceded all cases of acquired drug resistance. Burhan[21] investigated the relation between plasma concentrations of RIF, INH, PZA and culture results. Even if drug concentrations were below the reference values no relationship between post-dose concentration and culture conversion at 8 weeks was recorded. A post-hoc analysis showed that patients with low PZA levels and extensive lung lesions were at risk of one positive culture at week 4, 8 or 24/32. Similar result was obtained by Chideya[22] that found **that** a low PZA $C_{\max}$ was associated with worse outcomes in 255 TB patients from Botswana (where 69% were HIV coinfectd). A Danish small prospective study on 32 patients showed that 2h post-dose RIF and INH plasma concentrations were below the recommended ranges in the majority of patients and therapy failure occurred more frequently when RIF and INH concentrations were both below the normal ranges[23] A critical issue for predicting treatment outcome may be the number

1 of concomitantly underdosed drugs as reported in a few observations.^{20,23} Conversely, a
2 retrospective report on 17 Swiss patients[24], showed that despite low plasma concentrations the
3 outcome was good in the whole small sample.

4 While the ATDS' synergistic effect is well known, an innovative study described the impact of PK
5 on the sterilizing activity of the multidrug regimen[15]. The results showed that RIF $C_{max} > 8.2$
6 mg/L and PZA AUC/MIC > 11.3 interacted positively on sterilizing activity (measured as Beta-
7 slope of decline of bacillary burden in the sputum). In patients with RIF AUC < 35.4 mg*h/L an
8 increase in PZA AUC/MIC and/or ETB C_{max}/MIC increased the beta-slope. On the other hand an
9 increase in INH C_{max} decreased the sterilizing activity. This apparent antagonist effect of INH on
10 activity of RIF is consistent with previous studies on hollow fiber system where short interval
11 between administration of RIF and INH resulted in lower bactericidal and sterilizing effects[25].

12 Jindani[4], conversely, found that ETB had a sterilizing effect but it was judged to be antagonistic
13 to RIF's one: a possible explanation could be that ETB may increase treatment sterilizing effect in
14 patients with low RIF concentrations. At a higher RIF exposure, the effect of ETB is masked by the
15 higher sterilizing effect of RIF, so that the overall effect is less than that of adding the effects of two
16 drugs, manifesting as apparent antagonism.

17

18 A high inter- and inpatient variability in drug serum concentrations have been often observed and
19 further complicate the interpretation of PK results.

20 Therapeutic drug monitoring (TDM) might be a useful tool and dose-optimization has proved to be
21 beneficial in small non-controlled studies.

22 The proposed therapeutic ranges of plasma C_{max} , normally used as reference[26], are based on
23 concentrations achieved by standard doses in healthy volunteers in controlled phase I studies and
24 assumed to be effective in patients.

25 Data from real world report an improved outcome performing TDM in daily practice[7,8]. Low
26 plasma concentrations seems related to drug-drug interactions (DDIs), use of fixed coformulations,

malnutrition, diabetes and coinfections[27–29].

New methods for performing TDM are promising to implement sample collection in remote areas and to overcome technical issues (including the need for cold chain for storing samples).

One of these methods is the use of dried blood and plasma spots (DBSs/DPSs). They require a smaller blood volume than conventional venous blood sampling. These devices can be shipped at room temperature[30].

Regarding antitubercular drugs, limited data have been published. Assays with DPSs for RIF[31], RPT and several second line drugs have been developed.[32] To our knowledge, PZA and INH methods have been developed by Allanson *et al*: technical issues due to incomplete stability were reported for INH.[33]

Although AUC/MIC is the most reliable PD parameter for ATDs, estimating AUC needs several samples and limited samples strategies (LSS) have been developed to determine what sampling time is most informative of the AUC. In the past, collection at 2 hours captured C_{max} and the 6-hour sample distinguished between delayed absorption and malabsorption[34]. Population pharmacokinetic models predicted AUC from 0 to 24 hours with optimal sampling at time points 1, 3, 8 hours post-dose for RIF and 2, 6 (with also good estimation of C_{max}) hours post-dose for levofloxacin and 1, 4 hours post-dose for amikacin and kanamycin, respectively[35–37].

2.4 First-line drugs characteristics and PK/PD relationships (see Table 1)

2.4.1 Rifampicin (RIF)

RIF is a key sterilizing drug in the treatment of tuberculosis with relatively low early bactericidal activity usually administered at 8-12 mg/kg. RIF blocks the transcription inhibiting the bacterial DNA-dependent RNA polymerase. Mutations in the *rpoB* gene that

codes for the beta-subunit of the RNA polymerase are responsible for resistance to RIF. The MIC of RIF is 0.15-0.5 µg/mL.

It is metabolized by a liver esterase (arylacetamide deacetylase) and is a potent inducer of PXR-mediated pathways, increasing its own and other compounds' clearance. Auto-induction has been reported to take about a week and full induction takes about three to four weeks[38]. This causes a decline in the AUC and terminal half-life over the first weeks of administration. The best size predictor for RIF clearance is fat-free mass instead of total body weight and it should be used to optimize dose. Antiacids do not affect the absorption of RIF. Simultaneous intake of high-fat food decreases RIF C_{max} by 36% (AUC is less affected) and increase T_{max} by 103%.[39] In most patients the target RIF C_{max} is 8 to 24 µg/mL after 600 mg of oral dose and an increased dose is recommended if C_{max} is less than 6 µg/mL.

Several evidences point out that RIF dose is at the lower limit of optimal efficacy and that the maximum effective dose has yet to be found[40]. The consensus among experts on the use of higher doses is increasing dramatically, as shown by growing data. A dose range trial from Boeree and colleagues showed safety of two weeks of RIF up to 35 mg/kg[41]. A higher dose (13 mg/kg intravenously) improved treatment outcome in Indonesian TB meningitis patients as reported by Ruslami[10], results from HIRIF trial with 3 study arms of 10, 15, 20 mg/kg are expected to be presented soon[42] ~~is ongoing~~. Last year, preliminary results of PanACEA MAMS-TB-01 trial were presented and two weeks high-dose (up to 35 mg/kg) RIF in combination with INH, PZA and ETB showed a significant shortening of time to culture conversion over 12 weeks. Data about full study have still to be published[43].

Conversely, a study from Heemskerk and colleagues did not find a higher survival rate with “intensified” treatment for tuberculous meningitis (included 15 mg/Kg of RIF and 20 mg/kg

of levofloxacin) than that with standard treatment, but was argued that possibly the RIF dose was suboptimal[44,45].

Some other clinical experiences have been conducted and TDM-based increased RIF dosage led to improved outcome[7,46,47].

Diacon and colleagues[48] found almost the double 2-day early bactericidal activity (EBA) and higher AUC (171 versus 100 ug* h/ml) at 20 mg/kg comparing to 600 mg/die but C_{max} did not differ in this study.

Moreover a non linear increase in exposure might be observed because of saturation of hepatic extraction, but a model-based evaluation showed saturation of RIF clearance already at doses of about ≥ 450 mg, confirming previous studies. This could explain the non linearity of RIF concentration with dose, underexposure of lower-weight patients and the correlation between faster RIF absorption and higher bioavailability[49]. RIF is a potent inducer of pregnane X receptor mediated expression of CYP3A4 in liver and in intestine and plasma concentration of several CYP3A4 substrates are reduced (e.g. HIV protease inhibitors, oral contraceptives, azoles, statins, methadone and quinidine). It induces several other CYPs (CYP1A2, CYP2D6), phase II enzymes and efflux transporters. It inhibits OATP1B1, an organic transporter protein expressed by hepatocytes responsible for the uptake of many drugs into portal circulation.[50]

2.4.2 Rifabutin (RFB)

RFB is derived from rifamycin S. It inhibits DNA-dependent RNA polymerase leading to suppression of RNA synthesis. It is mostly used in HIV co-infected patients because it has fewer drug interactions with antiretroviral agents (see section 2.8.2) [51]. It is a weaker CYP3A inducer than RIF (60% less) and is also metabolized by CYP3A4 giving the rise to bidirectional interactions. Standard dose is 300 mg/day, but dose adjustment is recommended with antiretroviral therapy. The C_{max} increases proportionally with increasing

the dose from 300 mg to 1200 mg/day. Concomitant intake of food decreases the rate of its absorption.

2.4.3 Rifapentine (RPT)

RPT is a cyclopentyl derivative of RIF with a longer half-life (14–15 hours). Its development held the hope that it would have allowed highly active once-weekly therapy; it is intermediate between RFB and RIF in activity as inducer of hepatic microsomal drug metabolizing P450 enzymes.

TBTC Study 22 compared once-weekly regimen of INH and RPT with twice weekly INH and RIF in the continuation phase of treatment for pulmonary tuberculosis in HIV-positive and HIV-negative patients. Acquired rifamycine monoresistance among HIV-positive patients arm led to the closure of HIV-seropositive arm of the study.[52]

The hypothesized reasons for the unexpected results were: the inadequate dose of RPT (600 mg) and the inferior activity of INH due to the shorter half-life or the patients' acetylator status. A study by Weiner and colleagues in 2003 found that low INH plasma concentrations were associated with failure and relapse with once-weekly INH/RPT regimen[53].

Higher dosages of RPT were safely administered in following trials (RIFAQUIN study where RPT was used at 900 mg twice weekly and 1200 mg once weekly [54] and PREVENT TB study where RPT was used at 900 mg once weekly[55]). TBTC Study 29 compared RPT 600 mg daily with RIF 600 mg daily administered without food and it was safe, well tolerated, and as effective as RIF. [56]

Population pharmacokinetic studies showed that increasing the dose of RPT led to a minor bioavailability of the drug and less-than-dose-proportional pharmacokinetics but no plateau in exposures from 450 mg to 1800 mg was observed. [57] Studies to assess the safety, activity and pharmacokinetics of higher daily RPT doses in patients with active TB are needed.[58]

Currently, RPT is only available in US and, according to CDC guidelines[59], its use is recommended for the treatment of latent TB infection at the dose of 1200 mg with INH given once weekly for 12 weeks. It is also an option in the continuation phase of treatment for multi-sensitive TB in selected patients (HIV-negative patients without cavitory lesions and negative culture at 2 months of treatment[60]) at the dose of 600 mg with INH 900 mg once weekly in uncommon situations where more than once-weekly DOT is difficult to achieve. In 2010, European Commission assigned to RPT orphan drug status for TB treatment.

2.4.4 Isoniazid (INH)

INH is a prodrug, converted by mycobacterial enzyme *katG* to its active form. The mechanism of action is to inhibit the mycolic acid synthesis, disrupting the bacterial cell wall.[61] Mutations in *katG* and *inhA* genes are responsible for main mechanisms of INH resistance.[62]

INH has the highest early bactericidal activity (EBA) and acts against replicant extracellular mycobacteria. Its effect rapidly decreases after first days and its activity is associated with AUC and acetylator status. MIC ranges from 0.01 to 0.25 µg/mL. Studies investigating EBA activity have shown that maximum achievable EBA with clinically tolerable doses[63] was ~~with~~ at plasma concentrations of 2-3 µg/mL. It is recommended to give INH on empty stomach because food and antacids reduce INH C_{max} (high-fat meal causes a drop of 51% of C_{max}).

2.4.5 Pyrazinamide (PZA)

Pyrazinamide's mechanism of action is still not well defined and the drug appears to act, at least partially, by acidifying the cytoplasm of the cell. It is a prodrug that requires conversion to pyrazinoic acid (POA) by an amidase encoded by *pncA*. Mutation of this

gene is the more common cause of PZA resistance. A study in mice found that systemic delivery of POA was not sufficient to reduce bacillary burden, even if POA concentration in plasma, ELF (epithelial lining fluid) and lung lesion were similar to those produced by effective doses of PZA. New technics exploring delivering of POA at the site of infection[64] (into macrophages or intrapulmonary with adjunct inhalation therapy[65]) are ongoing. PZA has the potential effect of shortening treatment duration due to its great sterilizing activity. A trial exploring a regimen containing PZA, pretomanid and moxifloxacin showed efficacy at week 8, even in MDR-TB strains[66]. Recommended therapeutic range is 20-60 ug/mL.[26] Coadministration of allopurinol with PZA decreases pyrazinic acid clearance and causes acid uric accumulation due to inhibition of acid uric excretion[67].

Recent hollow fiber PK/PD study demonstrated that PZA's sterilizing effect was best explained by the AUC/MIC ratio, whereas resistance suppression was linked to T>MIC. Monte Carlo simulations revealed that doses higher than the currently recommended 2 g/day would have a better likelihood of achieving the AUC/MIC ratio associated with 90% of maximal effect, but safety concerns arise. PZA serum clearance has been shown to increase with increases in body weight[14].

2.4.6 Ethambutol (ETB)

ETB is a semisynthetic antibiotic which is bacteriostatic against *Mycobacterium tuberculosis*. ETB acts by inhibiting arabinosyl transferase enzyme, thus blocking the synthesis of arabinogalactan, which forms the mycobacterial cell wall.[68]

Mutations in *embB* gene that code for arabinosyl transferase enzyme are related with ETB resistance (MIC above 5 µg/mL). Resistance to ETB is higher in INH-resistant strain due to the correlation with mutation at *katG* Ser315 and *iniA*, which encodes an efflux pump transporter.

Concentrations measured in lung tissue, ascitis and pleural fluids are far higher than ones reached in plasma. ETB does not penetrate intact meninges, but in patients with TB meningitis the penetration increases by 10-50%. Aluminium-containing antacids decreases the C_{max} by 28% and AUC by 10%. Although mechanisms of sex-related differences in drug concentration are poorly understood lower ETB concentrations were found in female patients. In the same study albumin levels were inversely correlated with concentrations and the reason for this is unclear but is possibly related to altered pharmacokinetics in more severe diseases or malnutrition[28]. Recommended plasma concentrations are between 2 and 6 µg/mL. Some reports suggest that increasing the dose to 25 mg/kg/daily would be the preferred regimen for most patients, monitoring for toxic effects.[69]

2.4.7. Streptomycin (S)

Streptomycin, discovered almost 70 years ago, was the first agent of the aminoglycosides class to be used for TB treatment, promptly replaced by INH. Its use is limited by relatively high rates of resistance (particularly in high incidence countries); current guidelines recommend its administration as fourth drug in multisensitive TB treatment (as alternative to ETB).

Aminoglycosides act mostly as protein synthesis inhibitors both as 30S-subunit ribosome blockers and interference with proofreading process. They also disrupt the integrity of bacterial cell membrane.

While S is not usually included with second-line drugs it can be used as the injectable agent of the core MDR-TB regimen if none of the three other agents (amikacin, capreomycin and kanamycin) can be used and if the strain can be reliably shown to be sensitive. However S resistance does not play a part in the definition of XDR-TB and that DST (Drug Susceptibility Testing) results are not considered accurate[70].

Streptomycin resistance has been ascribed to mutational changes in *rpsL* and 16-S ribosomal RNA genes involving ribosomal binding protein or the ribosomal binding site. Isolates resistant to S are not cross-resistant to amikacin, kanamycin, or capreomycin. The members of the aminoglycoside family share the potential for nephrotoxicity, ototoxicity and rarely neuromuscular blockade. Intramuscular injection of 1 g yields peak plasma concentration of 35-45 µg/mL and it is virtually excluded from SNC. Recommended dosage in younger adults with normal renal function is 15 mg/kg/day IM. The drug can be safely given IV when needed, although is not approved for such use[71]. In patients with reduced renal function is recommended a dose of 15 mg/kg twice/thrice-a-week.

2.5 Second-line drugs characteristics and PK/PD relationships (Table 2-3)

2.5.1 Fluoroquinolones

Fluoroquinolones act by inhibiting two bacterial enzymes, DNA gyrase and topoisomerase IV involved in DNA replication. They exhibit concentration-dependent killing and a post-antibiotic effect.[72] Limited data from human studies are available for evaluating the PD thresholds necessary for maximizing therapeutic success. The two most commonly FQ used for the treatment of MDR-TB are levofloxacin and moxifloxacin due to their high C_{max}/MIC profile. Recently, three major international multicentre phase III trials demonstrated that four different 4-month regimens did not provide as good a standard of care as the 6-month regimen[54,73,74]. DDIs (drug-drug interactions) between RIF and moxifloxacin have been reported. Moxifloxacin AUC is reduced by 27%, and the half-life decreased by 36%, although no change in the peak concentration in serum was identified. This effect seems to be mediated by increased activity of the sulfate conjugation pathway of moxifloxacin metabolism, because coadministration of RIF resulted in marked increases in levels of the

1 M-1 metabolite. Some authors suggest to increase moxifloxacin dose to 600 mg/day when
2 coadministered with RIF.[75][76]

3 A hollow fiber study determined that moxifloxacin was able to suppress the development of
4 resistance with freeAUC_{0-24h}/MIC of 53 µg*hour/ml. In clinical trial simulations
5 moxifloxacin 400 mg/day had a target attainment rate of only 59%, improved to 90% with a
6 dose of 800 mg; this was further confirmed in murine models but safety in humans has not
7 yet been established[14]. Resistance to FQ depends on substitution in the GyrA and/or GyrB
8 and is defined by the WHO as resistance to at least 2 µg/ml of ofloxacin. Sterilizing activity
9 of moxifloxacin decreases gradually against strains with increasing levels of resistance
10 (from low to high). Therefore among strains resistant to 2 mg/L ofloxacin identification of
11 moxifloxacin level of resistance is required[77].

13 **2.5.3 Capreomycin, amikacin and kanamycin**

14 Capreomycin, amikacin and kanamycin, according to new WHO classification, are
15 considered as a group (group B) because they are all administered by intramuscular or
16 intravenous injection, have similar pharmacokinetics and toxicity and are excreted by renal
17 route. Capreomycin is a polypeptide active against *M. tuberculosis*, including most MDR-
18 TB strains. MIC ranges from 1 to 50 µg/mL. The dose is 500 mg-1 g IM 5 times/week. If an
19 isolate is resistant to both S and kanamycin capreomycin should be used.

20 Amikacin is the most active in *vitro* aminoglycoside against *M. tuberculosis* as well as in
21 animal models. Limited data are available in human tuberculosis because of its cost and
22 relatively greater toxicity (as compared to S and capreomycin, in the US it replaced
23 kanamycin). The dose is 7-10 mg/kg five times/week and TDM is available in laboratories.
24 Amikacin and kanamycin are considered to be very similar and have a high frequency of
25 cross-resistance. Kanamycin is an aminoglycoside active against most S-resistant strains. It

has no clear advantage over amikacin, except for lower cost; the dose is 15 mg/kg IM, limited to 500 mg/day due to a certain risk of ototoxicity.

2.5.4 Other second-line drugs

Few data are available about PK/PD parameters of other second line drugs and data we have are mostly desumed from non-TB models[16].

Linezolid (LZD) is an oxazolidinone agent. It is active against gram-positive bacteria, including resistant strains. It is used in the treatment of nosocomial pneumonia, skin and soft tissues infections caused by gram-positive bacteria. As second-line agent it can be used in the treatment of MDR TB and belongs, according to last WHO update to C group. It acts by binding to the 50S subunit of bacterial/mycobacterial ribosome producing an early inhibition of protein synthesis.[78] LZD for other human pathogens is time and concentration dependent. In a study on TB patients the correlation between plasma concentrations and activity is linear at values AUC/MIC less than 120 but disappears once $T > MIC$ reaches 100% (where T/MIC is the cumulative percentage of the dosing interval that the drug concentration exceeds the MIC under steady-state condition)[79].

Gebhart and colleagues found that RIF, inducing P-gp expression, leads to increased clearance of LZD (reduction in LZD serum concentration up to 30%) supporting the hypothesis that P-gp expression plays a role in the potential interaction between the two drugs[80], but several reports confirmed the efficacy on this combination[81].

Bedaquiline is a novel diarylquinoline that acts by inhibiting the *M. tuberculosis* adenosine triphosphate (ATP) synthase. It was approved by US FDA in 2012 and by EMA (European Medicine Agency) in 2013. It is metabolized by CYP3A4 to M2 as main metabolite and a significant reduction in exposure results if coadministered with RIF or RPT.[82] MIC ranges from 0.03 to 0.12 ug/mL. Its activity against both susceptible and MDR strains seems

1 to be promising to shorten treatment duration. Food increases the bioavailability by
2 twofolds. It has an extensive tissue distribution and steady state is reached after 7 days with
3 a time-dependent bactericidal activity[83]. The dose is 400 mg/day for 14 days followed by
4 200 mg thrice-a-week. It has a synergic activity with PZA.[84] Its PK characteristics are
5 compatible with once a week administration.[85] There are concerns on safety because of
6 the cardiovascular toxicity and QT prolongation (see section 2.6). Animal reproduction
7 studies have failed to demonstrate a risk to the fetus, but no data on pregnant women are
8 available (for FDA pregnancy category B).

9 Delamanid is a nitroimidazole and inhibits mycolic acid synthesis. It has been approved in
10 2014 by EMA. It has a good oral bioavailability, enhanced with food and has a
11 concentration dependent bactericidal effect. The dose is 100 mg twice-a-day. MIC ranges
12 from 0.006 to 0.024 ug/mL in both susceptible and resistance strains. It is thought to be
13 primarily metabolized by albumin, with secondary contributions from P450 enzymes,
14 primarily CYP3A4. Delamanid resulted teratogenic in reproductive toxicity studies in
15 animals, but no data in humans.[86]

16 The use of the more recently approved drugs is currently recommended in adult patients
17 with pulmonary MDR-TB for 24 weeks when an effective treatment containing four
18 second-line drugs in addition to PZA cannot be designed and/or when there is documented
19 evidence of resistance (or intolerance) to any FQ or second-line injectable drug (the latter
20 specifically for delamanid). Additional indication for delamanid is the presence of risk
21 factors of poor outcome such as: advanced/extended disease, HIV coinfection, high sputum
22 bacillary load, low BMI, and comorbidities (e.g. diabetes mellitus). The concomitant use of
23 bedaquiline and delamanid is not allowed by manufacturers and is not recommended by
24 WHO (nevertheless a sequential use is permitted)[87]. Two case reports of co-administration
25 were published[88,89] and it may be considered in selected patients and in presence of
26 appropriate monitoring conditions.

Pretomanid (PA-824), another nitroimidazole, is in Phase II studies. It is a prodrug that needs to be activated by mycobacterial glucose-6-phosphate dehydrogenase. Surprisingly, it exhibits a time-dependent bactericidal activity[90]. MIC ranges from 0.015 to 0.25 ug/mL against susceptible and resistant strains. Concomitant intake of foods increase the absorption and it exhibits a high tissue penetration. Promising results have been observed in EBA studies with combination of pretomanid/bedaquiline/ pyrazinamide[91] and pretomanid,/moxifloxacin/pyrazinamide (at 2[92] and 8 weeks[66]).

2.6 Pharmacokinetics and toxicity

Combination antitubercular treatment is associated with a significant incidence of ~~drug-associated~~ side effects: preventing toxicity might be beneficial also in terms of treatment interruption (estimated approximately at 5%), failures and selection of resistance[93]. Clinically relevant adverse effects include nausea, rash and occasional hepatotoxicity.

Concentration-dependant toxicity has been observed for ETB (optical neuritis) and PZA (hepatotoxicity), whereas for INH and RIF it is still uncertain[94,95].

RIF-induced hepatitis occurs in up to 2.5% and it does not seem to be dose related even with higher doses[96]. Intermittent regimens with higher RIF doses (1200 mg or more) seem to be rather related with higher risk of flu-like syndrome[97][98][99].

RFB can cause neutropenia and anterior uveitis and the risk appears to increase as RFB and 25-desacetyl-RFB exceeds 1 µg/mL.[9]

Periphery neuropathy, through the increase of the excretion of pyridoxine, is a rare INH dose-dependent adverse event. Patients at increased risk are those with HIV infection, diabetes, renal failure, alcoholism, malnutrition and pregnant/lactating women. Supplemental pyridoxine (vitamin B₆) is recommended at the dose of 150 mg 3 times per week. In lactating women taking INH,

supplementation of pyridoxine has to be administered to newborns as well for the passage through breast-feeding.

Regarding second-line drugs few data are available about toxicity related with plasma concentrations.

The primary concerns with aminoglycosides are auditory, vestibular and renal toxicity[100] and seem related to higher cumulative dose and older age.

Higher doses of moxifloxacin (600-800 mg) are being studied but dose escalation needs particular attention due to the risk of QT prolongation.

Data on LZD are mainly derived from gram-positive bacterial infections, its use is limited by its long-term adverse effects, including myelosuppression, lactic acidosis, ocular and peripheral neuropathy. The mechanism through toxicity occurs is not perfectly understood and the dose for mycobacteria has not yet clearly been established, even if 600 mg daily seems to be generally accepted. Maintenance of a serum LZD C_{min} between 2 and 7 $\mu\text{g/mL}$ has been suggested as a step for improving safety outcomes while retaining appropriate efficacy.

Bedaquiline prolongs QT and this effect extends for weeks after drug discontinuation. A study on healthy volunteers did not observe effect of a single incremented dose of 800 mg on QT and no association were found between QT and bedaquiline or M2 (major metabolite) plasma concentrations[101].

Delamanid may affect the length of QT interval as well: this appears to be dose-related and increasing over the initial 6–10 weeks of treatment. The effect has been linked to delamanid's major metabolite DM-6705. Both CYP3A4 inducers and inhibitors may increase levels of DM-6705, necessitating more intensive cardiac monitoring in such settings[86].

2.7 Pharmacogenetics

The interindividual differences genetically determined play a relevant role in designing a tailored treatment approach. Historically metabolizing phenotypes (later discovered to be associated with *NAT-2* genetic variants) have been associated with INH metabolism and toxicity; recently several pieces of evidence have been published on the effect of single nucleotide polymorphisms (SNPs) in genes encoding for proteins involved in drug disposition.

2.7.1 Rifampicin and PG

RIF is a substrate of P-glycoprotein and OATP1B1; the latter is an influx transporter mainly expressed in basolateral membrane of hepatocytes and that facilitates RIF uptake into hepatocytes. Genetic variants in *SLCO1B1* (encoding for OATP1B1) have been shown to affect the protein expression and activity.

In particular, Chigutsa and colleagues[102] undertook a study in South African patients with tuberculosis and found that *SLCO1B1* genetic polymorphism rs4149032 (which occurs at a high frequency in the black African population) is associated with reduced RIF concentrations. Patients heterozygous and homozygous for this polymorphism had reductions in the bioavailability (and, thus, AUC) of RIF of 18% and 28%, respectively. This study suggests that an increase in RIF dose would be desirable for carriers of the *SLCO1B1* polymorphism and a simulation showed that increasing the daily RIF dose by 150 mg in patients with the polymorphism would result in plasma concentrations similar to those of wild-type individuals and would reduce the percentage of patients with C_{max} below 8 mg/L (from 63% to 31%). Two other common non-synonymous *SLCO1B1* variants have been studied: rs2306283 (previously referred to as 388A>G) and rs4149056 (commonly referred to as 521T>C). These two variants are in partial linkage disequilibrium. Consequently, there are four important haplotypes: *SLCO1B1**1A, containing neither variant, *SLCO1B1**1B (rs2306238), *SLCO1B1**5 (rs4149056) and *SLCO1B1**15 (both). The *SLCO1B1**15 haplotype have been found to be associated with rifampin-induced liver injury

1 in a Chinese population and may have a role in cholestatic/mixed injury although other
2 studies in similar ethnic groups did not confirm such observation.[103,104]

3 Weiner and colleagues[105] studied the effect of genetic polymorphisms of *ABCB1*
4 (encoding for P-glycoprotein), *SLCO1B1* and *SLCO1B3* in patients with TB from different
5 regions (North America, Spain, Africa) and in healthy subjects. The results showed that
6 patients with *SLCO1B1* 463C>A variants (rs11045819) had a 36% lower RIF AUC
7 compared to CC genotypes.

8 Another investigated gene was the carboxylesterase 2 (*CES2*) because have been shown to
9 significantly affect the plasma concentrations of RIF. *CES2* is thought to be responsible for
10 the formation of the main metabolite of RIF by deacetylation[106].

11 Moreover mixed results have been published on the effect of *ABCB1* SNPs on RIF
12 exposure. *ABCB1* encodes for P-gp that is both a substrate of RIF and could be induced by
13 RIF. More studies are needed to investigate the potential to influence drugs transport and
14 intracellular accumulation[107].

16 **2.7.2 Isoniazid and PG**

17 INH is primarily metabolized by acetylation via N-acetyl transferase 2 (NAT2). The rate of
18 elimination of INH depends on NAT2 metabolic activity and the activity is controlled by
19 active alleles. According to *NAT2* genotype patients can be characterized as slow (without
20 any active alleles), intermediate (heterozygous for *NAT2*4*) and rapid acetylators
21 (homozygous for *NAT2*4*, wild type). Rapid acetylators are at higher risk of treatment
22 failure whereas slow acetylators may develop hepatotoxicity. Gene frequency for the slow
23 allele varies in different ethnic groups and geographical areas being 10% in Japanese and
24 Eskimos, 60% in Caucasians and subjects of African Ancestors and 90% in subjects from
25 the Middle-East.

A genotype-guided randomized and controlled trial investigated the rate of treatment failure and INH related liver injury (INH-DILI) in 172 Japanese patients with pulmonary TB[108]. Patients in the PGx-arm (pharmacogenetic guided arm) received 2.5 mg/kg, 5 and 7.5 mg/kg INH according to their slow, intermediate or rapid acetylator status, respectively while those in the standard dose arm received approximately 5 mg/kg. INH-DILI occurred in 78% of the slow acetylators in the standard-treatment (STD), while none of the slow acetylators in the PGx-treatment experienced either INH-DILI or early treatment failure. Among the rapid acetylators, early treatment failure was observed with a significantly lower incidence rate in the PGx-treatment than in the STD-treatment (15% vs. 38%).

2.7.3 Ethambutol and PG

A recent pharmacogenetic study from our group found an association between SNPs in *ABCB1*, *CYP24A1*, Vitamin D Receptor (*VDR*) gene and plasma/intracellular ETB concentrations. Further researches are needed to understand the clinical relevance of these findings[109].

2.7.4 Second-line drugs and PG

The influence of SNPs in genes encoding for transporters on FQ plasma concentrations has been investigated for moxifloxacin. Weiner and colleagues found that SNP 3435C>T (rs1045642) in *ABCB1* gene coding for P-gp have not influence on moxifloxacin PK levels. Therefore P-gp does not seem to be a major determinant of moxifloxacin disposition.[75]

So far no study was published about PG of aminoglycosides, except for one report of oral tobramycin absorption influenced by P-gp inhibitors.

The only published data regarding LZD and PG is the reported interaction between RIF and LZD that may be dependant on P-gp and therefore, potentially, on SNPs affecting P-gp activity.[80]

2.7.4 Hepatotoxicity and PG

The incidence of hepatotoxicity during antitubercular treatment varies from 2% to 28%[110]. The exact mechanism is unknown but toxic metabolites have a role in the development of it.

Investigations of genetic polymorphisms relating to drug induced hepatitis have been conducted and *CYP2E1* and *GST* genes resulted to influence the incidence of it.

CYP2E1 activity depends on INH blood concentrations. INH or its metabolite could both induce and inhibit *CYP2E1*. The variant *CYP2E1* genotype is more susceptible to the inhibition than the common genotype. The enhanced activity causes increased production of hepatotoxins and consequently increased risk of hepatotoxicity[111].

Furthermore *CYP2E1* polymorphisms were found to be related with the severity of antitubercular drug-induced hepatotoxicity[112].

GSTs enzymes are involved in detoxification of drugs and other chemical substances. Of the five encoding loci *GSTM1* and *GSTT1* were reported to be associated with hepatotoxicity in Western Indian population. Homozygous deletion at *GSTM1* and *GSTT1* loci could influence susceptibility to INH-induced liver toxicity[113].

2.8 Pharmacokinetics in special populations

Three groups of patients may be at higher risk of failure and/or side effects and therefore might benefit from personalization of ATD dosage: pediatrics, HIV-positive and diabetic subjects.

2.8.1 Pediatrics

Approximately 1 million of TB cases occur in children every year: interpatient variability in enhanced in children and the risk of under-dosing is consistent. In 2010, WHO recommended increased pediatric dosages for RIF (10–20 mg/kg), INH (7–15 mg/kg), PZA (30– 40 mg/kg), and ETB (15–25 mg/kg), which are higher than the adult recommended dose. To date, few studies have evaluated the PK of the WHO revised dosages in children[114]. A study on 127 Indian children showed increased concentration of INH, PZA and RIF with revised dosages, though the change was not significant for RIF. In this study no effect on outcome or due to malnutrition was observed. The effect of malnutrition, heavily affecting some settings, on pharmacokinetics of ATDs in children is not well known[115].

From these and other data much additional work is needed to characterize the PK and PD of the four first-line anti-TB drugs in pediatric patients.

The use of bedaquiline under 18 years old is off label. A PK and safety study is planned. So far no pediatric formulation is available. The dose is 6 mg/kg as loading dose followed by dose of 3 mg/kg.

Delamanid, through compassionate use, can be administered to children older than 6 years old or above 20 kg. Good PK data and safety have been shown in this population. Pediatric formulation is being developed. The dose is: 100 mg twice daily if >35 Kg; 50 mg twice daily if 20-35 Kg. A case series has been published (children between 8 and 17 years old) with good results.[116]

2.8.2 HIV-positive patients

TB is the most frequent infection in people living with HIV accounting for one third of deaths. In Sub-Saharan Africa most of the people with TB are HIV positive and death rate by TB infection are higher in this population[1]. Treatment for HIV infected patients do not require any adjustment in doses except that intermittent regimens are no longer recommended, as stated by international guidelines, due to the increased risk of relapse, failure and acquired RIF resistance[117,118].

1 The effect of HIV co-infection on the pharmacokinetics of the four first-line anti-TB drugs (and
2 treatment outcome) seems to be largely dependent on the patient's clinical status and on the
3 concurrent medications the patient is receiving. In some of the earlier studies[119], patients with
4 advanced HIV/AIDS showed a significant decrease in plasma levels of the first-line anti-TB
5 drugs; recent data did not confirm these observations.[120]

6 Clinically relevant DDIs have been reported between ATDs and antiretroviral drugs (ARVs).
7 Rifamycins are potent inducers of phase I (e.g. CYP450) and phase II (e.g. UGT) liver enzymes
8 and may reduce plasma concentrations of concomitant drugs metabolized by these enzymes.

9 Guidelines recommend the use of RIF with efavirenz (at standard dose, 600 mg), raltegravir
10 (exposure to standard dose of 400 mg twice-a-day seems to ensure adequate raltegravir
11 concentrations, but more data are needed[121]) and dolutegravir (doubling the dose, 50 mg
12 twice-a-day). The extent and direction of effect of RIF on efavirenz seems to be dependant on
13 *CYP2B6* genotype: the presence of *CYP2B6**6/*6 genotype is associated with slow efavirenz
14 metabolism, and other alternative metabolic pathways gain importance (CYP1A2, CYP2 A6,
15 CYP3A4/5). Higher efavirenz concentration has been found in patients harbouring haplotype
16 *CYP2B6**1/*6 and expecially *CYP2B6**6/*6. This increase in EFV plasma exposure under TB
17 regimen it can be partially explained also by an inhibitory effect of isoniazid (usually in the TB
18 regimen) on alternative metabolic pathways.[122] RIF is contraindicated with protease inhibitors
19 (PI) because causes relevant (50-80%) decreases in PI concentration: higher dose of
20 lopinavir/ritonavir (400/400 mg twice daily) may be necessary but higher incidence of liver and
21 gastro-intestinal toxicity was reported. Population pharmacokinetic models suggested that
22 darunavir/ritonavir (1600/200 mg once daily, 800/100 mg twice daily and 1200/150 mg twice
23 daily) could potentially overcome reduced darunavir concentrations with RIF.[123] This is a
24 significant problem in patients on second-line ARV regimens (often receiving PIs) since RFB is
25 expensive and often unavailable.

RFB is a less potent inducer than RIF and RFP; however its main metabolite (25-desacetyl-RFB) is a CYP3A4 substrate. Co-administration of RFB with potent CYP3A4 inhibitors (such as ritonavir and cobicistat), may increase the risk of adverse effects such as anterior uveitis. Consequently, current guidelines recommend modifying RFB doses when administered with PI/r, although there is a lack of international consensus as to the optimal dose: 150 mg every other day has been associated with treatment failure and selection of RIF-resistant strains.[124] Evidences favor the administration of RFB 150 mg every day although 150 mg thrice-a-week is recommended with atazanavir/ritonavir (for the increase in RFB and 25-desacetyl-RFB C_{max} and AUC). [51] A dose-increase to 450 mg is suggested when RFB is co-administered with efavirenz: no other dose-adjustment is currently suggested. Coadministration of rilpivirine is contraindicated. [125]

Regarding bedaquiline no major interactions are expected with the use of integrase inhibitors: on the contrary administration of CYP3A4 inducers and inhibitors should be avoided.[82][126] Little effects were seen with delamanid (lopinavir/ritonavir was associated with a 20% increase in delamanid exposure and a 30% increase in delamanid's metabolite DM-6705). South african cohort observed good clinical outcomes in a cohort of HIV-positive patients largely treated with lopinavir/ritonavir.[86]

2.8.3 Diabetic patients

Type 2 diabetes mellitus (DM) is a strong risk factor for TB infection and is associated with a slower response to treatment and with higher mortality rates. Some diabetic patients experience delayed or reduced drug absorption: the results of several observations on ATDs plasma concentrations are however heterogeneous. In some studies, DM was associated with decreased plasma levels of RIF and INH[27,127], whereas in others, there was no clear relationship between plasma concentrations of first-line ATDs and DM[128,129]. Consequently the

relationship between low plasma concentrations and poor outcomes need to be further studied in diabetic patients in order to identify other potential predictors and tailor antiTB treatment.

2.9 Intralesion, intracellular and intrabacterial pharmacokinetics

The sites of action of ATDs in pulmonary tuberculosis are the tissue compartments with pulmonary lesions and specifically drugs have to be in adequate concentrations in the ELF, in alveolar macrophages and inside mycobacteria. Despite the efficacy of antitubercular regimen little is known about the penetration of drugs and if this aspect plays a role in the long needed combination therapy. Considering that drug concentrations are associated to treatment outcome lesion penetration may contribute to it for the relation with incidence of relapse or the development of phenotypic drug resistance. Determination in venous plasma may not correctly predict real exposure of drugs to organs and to different components of a lesion.

Moreover inoculum effect (the variation of MIC according to the number of bacterial population) and phenotypic tolerance (variation of MIC according to metabolic state of subpopulations) at the site of infection may have a relevant role in determining the efficacy of regimen and the selection of resistance.

Kjellsson and colleagues[130] found in a rabbit model that RIF, PZA and INH (RIF>PZA>INH) reached lower lesion concentrations in comparison to plasma ones, although RIF seems to accumulate in uninvolved lung tissue. In contrast moxifloxacin displayed the highest distribution in lesions, using tissue homogenate.

MALDI-MSI technology was applied by Prideaux and colleagues[131] to observe that, within the granuloma, moxifloxacin reached very low levels in the caseum (where typically reside persister mycobacteria) in comparison to the cellular granuloma regions. We may speculate that this is the reason why FQ-using shortening trials failed. PZA seems to be the only agent with good diffusion into caseum and be active against persister mycobacteria. Prideaux and colleagues[132] described

1 in human lung lesions, using very refined methods, the distribution of these drugs, confirming
2 previous results. Besides, lipophilic drugs (RIF, RPT, bedaquiline, pretomanid and clofazimine)
3 seems to be more active than hydrophilic agents (INH, PZA, ETB, amikacin, moxifloxacin) against
4 dormant mycobacteria in hypoxic condition as within cellular granuloma, whereas in the necrotic
5 centre the pH ranges between 7.2 and 7.4.[133]

6 Haartkoorn et al[134] investigated INH, ETB and RIF activity inside infected macrophages. RIF is
7 a drug with excellent activity against intracellular bacilli, concentrating from 2 to 5-fold in
8 macrophages, however higher concentrations were required to kill intracellular mycobacteria. INH
9 modulated the growth of mycobacteria at similar concentrations inside and outside the cell. Dhillon
10 found, in animal model, that PZA and ETB expresses bacteriostatic activity in macrophages with a
11 MIC equivalent to extracellular one.[135]

12 From previous studies aminoglycosides have intracellular/extracellular (I/E) ratio that is lower than
13 1, INH has an I/E ratio of around 1, RIF has an I/E ratio of between 2 and 5, and ETB and the
14 macrolides have I/E ratios ranging from 10 to >20[136,137].

15 Some experience have been made measuring drug concentrations inside PBMCs (peripheral blood
16 mononuclear cells) for being easily and readily collectable, and possibly a good surrogate of
17 alveolar macrophages, partially confirming previous results of I/E ratio[138,139][140]. Reduced
18 permeability of *M. tuberculosis* to drugs further contributes to the inferior susceptibility of the
19 quiescent bacterial population to the therapy. Interestingly, studies have reported that intrabacterial
20 penetration of FQ is reduced in non replicating mycobacteria and is only partially explained by
21 efflux. Moreover polyamine (organic compounds present both in eukaryotic and prokaryotic cells)
22 inhibit uptake of fluoroquinolones and accumulate with inflammation contributing to the
23 development of dormancy for their tuberculostatic effect[141].

25 3. Conclusion

Pharmacokinetic variability of ATDs is driven by multiple factors and reported data point the way toward individualized dosing. Maximizing efficacy of existing drugs and minimizing toxicity on a large scale with TDM and pharmacogenetics will likely show benefit. More data are needed especially for second-line drugs and new released drugs.

Efficacy, safety, tolerability and potential sterilizing effect of increased rifampin dosing need to be further explored because promising results from EBA studies are limited to bactericidal activity. *NAT2* influence on pharmacokinetics offers an example of how dosing can be adjusted for different patient genotype and could be extended to *SLCOB1* polymorphisms.

4. Expert opinion

Ending the tuberculosis epidemic is one of the key goals of the WHO post-2015 strategy. It will be achievable with the widespread and well-tolerated treatment administered to all precociously diagnosed patients with tuberculosis and with the optimized therapy for patients harbouring resistant strains. The best use of currently available drugs is critical in delivering efficacious and safe treatment and to implement shorter combinations: the failure of fluoroquinolones shortening trials tells us that we need to better understand the tissue penetration of antibiotics. ATDs' plasma concentrations are associated with treatment efficacy but clear cut off have not being defined and the majority of patients are cured despite very low plasma levels; yet significant variability and underexposure of ATDs are common features and the relationship with concentrations at the site of action (intra-macrophage and intra-lesional) are poorly understood.

Therapeutic drug monitoring may be suggested in groups at risk of failure, toxicity or lower exposure such as children and adolescents, HIV-positive individuals, diabetics, patients with renal or liver impairment or subjects taking potentially interacting drugs. Its use in those with delayed response to treatment has been tested and we strongly recommend its application. Underexposure, especially if involving more than one compound, requires adequate dose adjustments and further controls. The lack of PK laboratories (performing HPLC/UPLC or GC techniques) calls for

1 capacity building in centralized facilities and for the use of dried blood/plasma spots for safe and
2 cheap samples delivery. Sequential samples or application of Limited Samples Strategy (LSS) to
3 calculate AUC are preferred rather than a 2-hour post-dose sample to correctly estimate drugs' peak
4 concentrations.

5 Furthermore the optimization of currently available first-line drugs involves their tailored per
6 kilogram dose, their once-daily administration, the correct relationship to food intake (fasted RIF,
7 INH and fed ETB and PZA) and the avoidance of potentially interacting drugs.

8 The individualization of ATDs' dose according to subjects' genetic variants require more
9 prospective data as well as controlled trials. In the meanwhile we collect, after patients' signing
10 written informed consents, *NAT2*, *SLCO1B1* and *PXR* genotypes. We are currently reducing INH
11 dose in *NAT2* slow metabolizers (4 mg/kg) and increasing RIF dose (to 15 mg/kg) in subjects with
12 loss of function in *SLCO1B1*.

13 Presumably an increased RIF dose will be soon recommend for all patients independently from
14 disease localization, if safety concerns will not be arisen from ongoing studies. In the meanwhile we
15 also use a 15 mg/kg RIF dose in patients with TB meningitis and in those with low RIF $C_{\max}$
16 concentrations ($<8 \mu\text{g/mL}$).

17 Insufficient knowledge on treatment in pediatric population worths research investments in
18 selecting the appropriate dose: *in vivo* to *in vitro* extrapolation modelling might be a promising
19 option to study the PK in fragile and rapidly changing patients.

20 Finally cellular and tissue pharmacology need to be assessed and new formulations explored (such
21 the promising nanoformulations allowing for slow and/or targeted release of drugs) in order to tailor
22 antitubercular treatment dose and duration to patients' and disease characteristics. We believe this
23 may be the future of antiTB pharmacology: the goal would be to have an imaging technique
24 allowing us to estimate drug penetration *in vivo*. Positron emission tomographies may allow to
25 identify zone in which tracer-associated drugs are insufficiently penetrating: this may inform
26 clinical decisions such as dose increase, use of second-line drugs and even referral for surgical

removal of lesions. An integration of drugs' plasma information with tissue specific PK/PD parameters could lead to optimization of existing drugs: physiologically based pharmacokinetic modelling is a promising field that may help designing informative trials.

One of the challenging areas in understanding PK/PD relationships of ATDs is the lack of early biomarkers for defining drug efficacy. While EBA is expensive and not related to sterilizing activity other markers are under investigation such as sputum and urine molecular studies and whole blood bactericidal activity (WBA), but the description of this topic is beyond the scope of this review. We envisage significant efforts in identifying cheap and sensitive early biomarkers of antimycobacterial activity and treatment response.

Tuberculosis is a challenging infection for the long needed treatment, multidrug regimen and potential toxicities and drug interactions. Only with global initiative and collaborations between researchers the open issues may be resolved: in the future we will be able to administer to all affected subjects the right drug at the right dose for the right patient.

References

(•=of importance, ••= of considerable importance)

[1] Tuberculosis factsheets <http://www.who.int/mediacentre/factsheets/fs104/en/>. Last access 30th January 2017.

[2] WHO post-2015 strategy. http://www.who.int/tb/post2015_strategy/en/. Last access 30th January 2017.

[3] Horsburgh CR, Barry CE, Lange C. Treatment of Tuberculosis. Longo DL, editor. N. Engl. J. Med. [Internet]. 2015 [cited 2016 Jun 17];373:2149–2160. Available from: <http://www.nejm.org/doi/10.1056/NEJMr1413919>.

[4] Jindani A, Doré CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. [Internet]. 2003 [cited 2016 Jun 24];167:1348–1354. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12519740>.

- 1 [5] Wallis RS, Maeurer M, Mwaba P, et al. Tuberculosis—advances in development of new
2 drugs, treatment regimens, host-directed therapies, and biomarkers. *Lancet Infect. Dis.*
3 [Internet]. 2016;16:e34–e46. Available from:
4 <http://www.sciencedirect.com/science/article/pii/S1473309916000700>.
- 5 [6] Ma Z, Lienhardt C, McIlleron H, et al. Global tuberculosis drug development pipeline: the
6 need and the reality. *Lancet (London, England)* [Internet]. 2010 [cited 2016 Jun
7 17];375:2100–2109. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20488518>.
- 8 [7] Magis-Escurra C, van den Boogaard J, Ijdema D, et al. Therapeutic drug monitoring in the
9 treatment of tuberculosis patients. *Pulm. Pharmacol. Ther.* [Internet]. 2012 [cited 2016 Jun
10 18];25:83–86. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22179055>.
- 11 [8] Babalik A, Babalik A, Mannix S, et al. Therapeutic drug monitoring in the treatment of
12 active tuberculosis. *Can. Respir. J.* [Internet]. [cited 2016 Jun 24];18:225–229. Available
13 from: <http://www.ncbi.nlm.nih.gov/pubmed/22059181>.
- 14 [9] Egelund EF, Alsultan A, Peloquin CA. Optimizing the clinical pharmacology of tuberculosis
15 medications. *Clin. Pharmacol. Ther.* [Internet]. 2015 [cited 2016 Feb 26];98:387–393.
16 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26138226>.
- 17 • **Interesting review regarding the current potential of TB drugs to shorten TB**
18 **treatment.**
- 19 [10] Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and
20 moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
21 *Lancet. Infect. Dis.* [Internet]. 2013 [cited 2016 Jun 21];13:27–35. Available from:
22 <http://www.ncbi.nlm.nih.gov/pubmed/23103177>.
- 23 • **Mortality benefit demonstrated in TB meningitis by optimizing dosing.**
- 24 [11] WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update - PubMed -
25 NCBI [Internet]. [cited 2017 Jan 22]. Available from: [https://www-ncbi-nlm-nih-](https://www-ncbi-nlm-nih-gov.offcampus.dam.unito.it/pubmed/27748093)
26 [gov.offcampus.dam.unito.it/pubmed/27748093](https://www-ncbi-nlm-nih-gov.offcampus.dam.unito.it/pubmed/27748093).

- 1 [12] ClinicalTrials.gov <https://clinicaltrials.gov/ct2/show/NCT02342886?term=pa->
2 824+moxifloxacin&rank=2. Last access 30th January 2017.
- 3 [13] WHO, The World Health Organization. Treatment of tuberculosis: guidelines. 4th Ed.
4 [Internet]. 2010;160. Available from:
5 <http://www.ncbi.nlm.nih.gov/books/NBK138741/#ch2.s3>. Last access 30th January 2017.
- 6 [14] Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: current
7 standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.
8 Pharmacotherapy. 2009;29:1468–1481.
- 9 [15] Chigutsa E, Pasipanodya JG, Visser ME, et al. Impact of nonlinear interactions of
10 pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in
11 tuberculosis. Antimicrob. Agents Chemother. [Internet]. 2015 [cited 2016 Jun 9];59:38–45.
12 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25313213>.
- 13 [16] Reynolds J, Heysell SK. Understanding pharmacokinetics to improve tuberculosis treatment
14 outcome. Expert Opin. Drug Metab. Toxicol. [Internet]. 2014 [cited 2016 Jun 17];10:813–
15 823. Available from: <http://www.tandfonline.com/doi/full/10.1517/17425255.2014.895813>.
- 16 [17] Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis
17 killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. [Internet].
18 2007 [cited 2016 Jun 24];51:3781–3788. Available from:
19 <http://www.ncbi.nlm.nih.gov/pubmed/17724157>.
- 20 [18] Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an
21 aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. [Internet]. 2003
22 [cited 2016 Jun 24];47:2118–2124. Available from:
23 <http://www.ncbi.nlm.nih.gov/pubmed/12821456>.
- 24 [19] Brindle R, Odhiambo J, Mitchison D. Serial counts of Mycobacterium tuberculosis in
25 sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in
26 treating pulmonary tuberculosis. BMC Pulm. Med. [Internet]. 2001 [cited 2016 Jun 24];1:2.

Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11737875>.

[20] Pasipanodya JG, McIlleron H, Burger A, et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. *J. Infect. Dis.* [Internet]. 2013 [cited 2016 Jun 17];208:1464–1473. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23901086>.

••The study presented shows that with standard TB therapy a high proportion of patients have low drug concentrations, which is associated with therapy failure and emergence of drug resistance.

[21] Burhan E, Ruesen C, Ruslami R, et al. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. *Antimicrob. Agents Chemother.* [Internet]. 2013 [cited 2016 Jun 21];57:3614–3619. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23689725>.

[22] Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. *Clin. Infect. Dis.* [Internet]. 2009 [cited 2016 Jun 21];48:1685–1694. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19432554>.

[23] Pahl JB, Johansen IS, Cohen AS, et al. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. *J. Antimicrob. Chemother.* [Internet]. 2014 [cited 2016 Jun 24];69:2841–2847. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25140577>.

[24] Meloni M, Corti N, Müller D, et al. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges. *Swiss Med. Wkly.* [Internet]. 2015;1–10. Available from: <http://doi.emh.ch/smw.2015.14223>.

[25] Srivastava S, Sherman C, Meek C, et al. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant *Mycobacterium tuberculosis* but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. *Antimicrob.*

Agents Chemother. [Internet]. 2011 [cited 2016 Jun 24];55:5085–5089. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/21896907>.

[26] Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs [Internet]. 2002 [cited 2016 Jun 24];62:2169–2183. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/12381217>.

••Comprehensive review of therapeutic drug monitoring for TB in clinical practice.

[27] Babalik A, Ulus IH, Bakirci N, et al. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus. Antimicrob. Agents Chemother. [Internet]. 2013 [cited 2016 Jun 24];57:5740–5742. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/23979746>.

[28] McIlleron H, Wash P, Burger A, et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. [Internet]. 2006 [cited 2016 Jun 24];50:1170–1177. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/16569826>.

[29] Heysell SK, Moore JL, Keller SJ, et al. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg. Infect. Dis. [Internet]. 2010 [cited 2016 Jun 24];16:1546–1553. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/20875279>.

[30] Calcagno A, Motta I, Milia MG, et al. Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi. Br. J. Clin. Pharmacol. [Internet]. 2015 [cited 2016 Feb 26];79:801–808. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/25377591>.

[31] Allanson AL, Cotton MM, Tettey JNA, et al. Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: a potential method for therapeutic drug monitoring. J. Pharm. Biomed. Anal. [Internet]. 2007 [cited 2017 Jan 11];44:963–969. Available from:

1 <http://linkinghub.elsevier.com/retrieve/pii/S0731708507002312>.

2 [32] Lee K, Jun S-H, Han M, et al. Multiplex Assay of Second-Line Anti-Tuberculosis Drugs in
3 Dried Blood Spots Using Ultra-Performance Liquid Chromatography-Tandem Mass
4 Spectrometry. *Ann. Lab. Med.* [Internet]. 2016 [cited 2017 Jan 23];36:489. Available from:
5 <http://www.ncbi.nlm.nih.gov/pubmed/27374716>.

6 [33] Vu DH, Alffenaar JWC, Edelbroek PM, et al. Dried blood spots: a new tool for tuberculosis
7 treatment optimization. *Curr. Pharm. Des.* [Internet]. 2011 [cited 2017 Jan 29];17:2931–
8 2939. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21834763>.

9 [34] Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an
10 update. *Drugs* [Internet]. 2014 [cited 2016 Jun 24];74:839–854. Available from:
11 <http://www.ncbi.nlm.nih.gov/pubmed/24846578>.

12 [35] Sturkenboom MGG, Mulder LW, de Jager A, et al. Pharmacokinetic Modeling and Optimal
13 Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with
14 Tuberculosis. *Antimicrob. Agents Chemother.* [Internet]. 2015 [cited 2016 Apr 11];59:4907–
15 4913. Available from:
16 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4505200&tool=pmcentrez&rend](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4505200&tool=pmcentrez&render_type=abstract)
17 [ertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4505200&tool=pmcentrez&render_type=abstract).

18 [36] Alsultan A, An G, Peloquin CA. Limited sampling strategy and target attainment analysis for
19 levofloxacin in patients with tuberculosis. *Antimicrob. Agents Chemother.* [Internet]. 2015
20 [cited 2016 May 18];59:3800–3807. Available from:
21 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4468713&tool=pmcentrez&rend](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4468713&tool=pmcentrez&render_type=abstract)
22 [ertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4468713&tool=pmcentrez&render_type=abstract).

23 [37] Dijkstra JA, van Altena R, Akkerman OW, et al. Limited sampling strategies for therapeutic
24 drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis.
25 *Int. J. Antimicrob. Agents* [Internet]. 2015 [cited 2016 May 29];46:332–337. Available from:
26 <http://www.ncbi.nlm.nih.gov/pubmed/26228464>.

- 1 [38] Smythe W, Khandelwal A, Merle C, et al. A semimechanistic pharmacokinetic-enzyme
2 turnover model for rifampin autoinduction in adult tuberculosis patients. *Antimicrob. Agents*
3 *Chemother.* [Internet]. 2012 [cited 2016 May 30];56:2091–2098. Available from:
4 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3318330&tool=pmcentrez&rend](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3318330&tool=pmcentrez&rendertype=abstract)
5 [ertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3318330&tool=pmcentrez&rendertype=abstract).
- 6 [39] Peloquin CA, Namdar R, Singleton MD, et al. Pharmacokinetics of rifampin under fasting
7 conditions, with food, and with antacids. *Chest* [Internet]. 1999 [cited 2017 Jan 29];115:12–
8 18. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9925057>.
- 9 [40] van Ingen J, Aarnoutse RE, Donald PR, et al. Why Do We Use 600 mg of Rifampicin in
10 Tuberculosis Treatment? *Clin. Infect. Dis.* [Internet]. 2011 [cited 2016 Jun 8];52:e194-9.
11 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21467012>.
- 12 [41] Boeree MJ, Diacon AH, Dawson R, et al. A dose-ranging trial to optimize the dose of
13 rifampin in the treatment of tuberculosis. *Am. J. Respir. Crit. Care Med.* [Internet]. 2015
14 [cited 2016 Jun 21];191:1058–1065. Available from:
15 <http://www.ncbi.nlm.nih.gov/pubmed/25654354>.
- 16 [42] Milstein M, Lecca L, Peloquin C, et al. Evaluation of high-dose rifampin in patients with
17 new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.
18 *BMC Infect. Dis.* [Internet]. 2016 [cited 2016 Sep 3];16:453. Available from:
19 <http://bmcinfectedis.biomedcentral.com/articles/10.1186/s12879-016-1790-x>.
- 20 [43] Boeree M, Hoelscher M. High-dose rifampin, SQ109 and moxifloxacin for treating TB: the
21 PanACEA MAMS-TB trial. Presented at the Conference on Retroviruses and Opportunistic
22 Infections, Seattle, February 25 2015. abstract. No Title.
- 23 [44] Heemskerk AD, Bang ND, Mai NTH, et al. Intensified Antituberculosis Therapy in Adults
24 with Tuberculous Meningitis. *N. Engl. J. Med.* [Internet]. 2016 [cited 2016 Jun 24];374:124–
25 134. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26760084>.
- 26 [45] Boeree MJ, Gillespie SH, Hoelscher M, et al. Therapy for Tuberculous Meningitis. *N. Engl.*

J. Med. [Internet]. 2016 [cited 2016 Jun 24];374:2187–2188. Available from:

<http://www.ncbi.nlm.nih.gov/pubmed/27248636>.

[46] Mehta JB, Shantaveerapa H, Byrd RP, et al. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. *Chest* [Internet]. 2001 [cited 2016 Jun 18];120:1520–1524. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11713129>.

[47] Te Brake L, Dian S, Ganiem AR, et al. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. *Int. J. Antimicrob. Agents* [Internet]. 2015 [cited 2016 Jun 24];45:496–503. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25703312>.

[48] Diacon AH, Patientia RF, Venter A, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. *Antimicrob. Agents Chemother.* [Internet]. 2007 [cited 2016 Jun 8];51:2994–2996. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17517849>.

[49] Chirehwa MT, Rustumjee R, Mthiyane T, et al. Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction. *Antimicrob. Agents Chemother.* [Internet]. 2016 [cited 2016 Jun 18];60:487–494. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26552972>.

[50] Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin : clinical relevance. *Clin. Pharmacokinet.* [Internet]. 2003 [cited 2017 Jan 29];42:819–850. Available from: <http://link.springer.com/10.2165/00003088-200342090-00003>.

[51] Yapa HM, Boffito M, Pozniak A. Critical Review: What Dose of Rifabutin Is Recommended With Antiretroviral Therapy? *J. Acquir. Immune Defic. Syndr.* [Internet]. 2016 [cited 2016 Jun 8];72:138–152. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26855245>.

[52] Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. *Tuberculosis*

- 1 Trials Consortium. *Lancet* (London, England) [Internet]. 1999 [cited 2017 Jan 22];353:1843–
2 1847. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10359410>.
- 3 [53] Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of
4 tuberculosis treatment with once-weekly isoniazid and rifapentine. *Am. J. Respir. Crit. Care*
5 *Med.* [Internet]. 2003 [cited 2016 Jun 21];167:1341–1347. Available from:
6 <http://www.ncbi.nlm.nih.gov/pubmed/12531776>.
- 7 [54] Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for
8 pulmonary tuberculosis. *N. Engl. J. Med.* [Internet]. 2014 [cited 2016 Jun 21];371:1599–
9 1608. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25337749>.
- 10 [55] Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for
11 latent tuberculosis infection. *N. Engl. J. Med.* [Internet]. 2011 [cited 2017 Jan 22];365:2155–
12 2166. Available from: <http://www.nejm.org/doi/abs/10.1056/NEJMoa1104875>.
- 13 [56] Dorman SE, Goldberg S, Stout JE, et al. Substitution of rifapentine for rifampin during
14 intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials
15 consortium. *J. Infect. Dis.* [Internet]. 2012 [cited 2017 Jan 22];206:1030–1040. Available
16 from: <http://jid.oxfordjournals.org/lookup/doi/10.1093/infdis/jis461>.
- 17 [57] Savic RM, Lu Y, Bliven-Sizemore E, et al. Population Pharmacokinetics of Rifapentine and
18 Desacetyl Rifapentine in Healthy Volunteers: Nonlinearities in Clearance and
19 Bioavailability. *Antimicrob. Agents Chemother.* [Internet]. 2014 [cited 2017 Jan
20 22];58:3035–3042. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24614383>.
- 21 [58] Weiner M, Bock N, Peloquin CA, et al. Pharmacokinetics of Rifapentine at 600, 900, and
22 1,200 mg during Once-Weekly Tuberculosis Therapy. *Am. J. Respir. Crit. Care Med.*
23 [Internet]. 2004 [cited 2017 Jan 22];169:1191–1197. Available from:
24 <http://www.ncbi.nlm.nih.gov/pubmed/14962821>.
- 25 [59] Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for
26 Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice

- Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin. Infect. Dis. [Internet]. 2016 [cited 2016 Sep 3]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27516382>.
- [60] Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet (London, England) [Internet]. 2002 [cited 2017 Jan 17];360:528–534. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12241657>.
- [61] Timmins GS, Deretic V. Mechanisms of action of isoniazid. Mol. Microbiol. [Internet]. 2006 [cited 2017 Jan 22];62:1220–1227. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17074073>.
- [62] Zhang Y, Young D. Molecular genetics of drug resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. [Internet]. 1994 [cited 2017 Jan 29];34:313–319. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7829406>.
- [63] Donald PR, Sirgel FA, Botha FJ, et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. [Internet]. 1997 [cited 2016 Jun 24];156:895–900. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9310010>.
- [64] Lanoix J-P, Tasneen R, O'Brien P, et al. High systemic exposure of pyrazinoic acid has limited anti-tuberculosis activity in murine and rabbit models of tuberculosis. Antimicrob. Agents Chemother. [Internet]. 2016 [cited 2016 May 18]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27139472>.
- [65] Mitchison DA, Fourie PB. The near future: improving the activity of rifamycins and pyrazinamide. Tuberculosis (Edinb). [Internet]. 2010 [cited 2016 Jun 24];90:177–181. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20382083>.
- [66] Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F MC. Efficiency and safety of the

combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant p. *Lancet* (London, England). 2015;May 2:1738–1747.

[67] Lacroix C, Guyonnaud C, Chaou M, et al. Interaction between allopurinol and pyrazinamide. *Eur. Respir. J.* [Internet]. 1988 [cited 2017 Jan 29];1:807–811. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/3229478>.

[68] Mikusová K, Slayden RA, Besra GS, et al. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. *Antimicrob. Agents Chemother.* [Internet]. 1995 [cited 2017 Jan 22];39:2484–2489. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/8585730>.

[69] Zhu M, Burman WJ, Starke JR, et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. *Int. J. Tuberc. Lung Dis.* [Internet]. 2004 [cited 2017 Jan 29];8:1360–1367. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15581206>.

[70] Implementing tuberculosis diagnostics: A policy framework (WHO/HTM/TB/2015.11) [Internet]. Geneva, World Heal. Organ. 2015. Available from http://apps.who.int/iris/bitstream/10665/162712/1/9789241508612_eng.pdf. Last access 30th January 2017.

[71] Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 7th Edition.

[72] Fish DN. Levofloxacin: update and perspectives on one of the original “respiratory quinolones”. *Expert Rev. Anti. Infect. Ther.* [Internet]. 2003 [cited 2017 Jan 24];1:371–387. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15482135>.

[73] Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. *N. Engl. J. Med.* [Internet]. 2014 [cited 2016 Jun 21];371:1577–1587. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25196020>.

[74] Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. *N. Engl. J. Med.* [Internet]. 2014 [cited 2016 Jun 21];371:1588–1598.

Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25337748>.

[75] Weiner M, Burman W, Luo C-C, et al. Effects of Rifampin and Multidrug Resistance Gene Polymorphism on Concentrations of Moxifloxacin. *Antimicrob. Agents Chemother.* [Internet]. 2007 [cited 2017 Jan 24];51:2861–2866. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17517835>.

[76] Nijland HMJ, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. *Clin. Infect. Dis.* [Internet]. 2007 [cited 2017 Jan 24];45:1001–1007. Available from: <http://cid.oxfordjournals.org/lookup/doi/10.1086/521894>.

[77] Fillion A, Aubry A, Brossier F, et al. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. *Antimicrob. Agents Chemother.* [Internet]. 2013 [cited 2016 Jun 24];57:4496–4500. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23836169>.

[78] Baietto L, Corcione S, Pacini G, et al. A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? *Curr. Drug Metab.* [Internet]. 2014 [cited 2016 Jun 6];15:581–598. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4435065&tool=pmcentrez&rendertype=abstract>.

[79] Dietze R, Hadad DJ, McGee B, et al. Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis. *Am. J. Respir. Crit. Care Med.* [Internet]. 2008 [cited 2016 Jun 18];178:1180–1185. Available from: <http://www.atsjournals.org/doi/abs/10.1164/rccm.200806-892OC>.

[80] Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. *Pharmacotherapy* [Internet]. 2007 [cited 2017 Jan 30];27:476–479. Available from: <http://doi.wiley.com/10.1592/phco.27.3.476>.

- 1 [81] Ashizawa N, Tsuji Y, Kawago K, et al. Successful treatment of methicillin-resistant
2 *Staphylococcus aureus* osteomyelitis with combination therapy using linezolid and
3 rifampicin under therapeutic drug monitoring. *J. Infect. Chemother.* [Internet]. 2016 [cited
4 2016 Jun 28];22:331–334. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26732509>.
- 5 [82] Svensson EM, Murray S, Karlsson MO, et al. Rifampicin and rifapentine significantly reduce
6 concentrations of bedaquiline, a new anti-TB drug. *J. Antimicrob. Chemother.* [Internet].
7 2014 [cited 2017 Jan 28];70:1106–1114. Available from:
8 <http://www.ncbi.nlm.nih.gov/pubmed/25535219>.
- 9 [83] Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of
10 the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. *Antimicrob. Agents*
11 *Chemother.* [Internet]. 2008 [cited 2016 Jun 18];52:2831–2835. Available from:
12 <http://www.ncbi.nlm.nih.gov/pubmed/18505852>.
- 13 [84] Ibrahim M, Andries K, Lounis N, et al. Synergistic activity of R207910 combined with
14 pyrazinamide against murine tuberculosis. *Antimicrob. Agents Chemother.* [Internet]. 2007
15 [cited 2017 Jan 29];51:1011–1015. Available from:
16 <http://aac.asm.org/cgi/doi/10.1128/AAC.00898-06>.
- 17 [85] Veziris N, Ibrahim M, Lounis N, et al. A once-weekly R207910-containing regimen exceeds
18 activity of the standard daily regimen in murine tuberculosis. *Am. J. Respir. Crit. Care Med.*
19 [Internet]. 2009 [cited 2017 Jan 29];179:75–79. Available from:
20 <http://www.atsjournals.org/doi/abs/10.1164/rccm.200711-1736OC>.
- 21 [86] Szumowski JD, Lynch JB. Profile of delamanid for the treatment of multidrug-resistant
22 tuberculosis. *Drug Des. Devel. Ther.* [Internet]. 2015 [cited 2016 Jun 18];9:677–682.
23 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25678771>.
- 24 [87] The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy
25 guidance-WHO. Available at:
26 http://apps.who.int/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdf

1 Last access 30th January 2017.

2 [88] Lachâtre M, Rioux C, Dû D Le, et al. Bedaquiline plus delamanid for XDR tuberculosis.

3 Lancet Infect. Dis. [Internet]. 2016 [cited 2017 Jan 29];16:294. Available from:

4 <http://linkinghub.elsevier.com/retrieve/pii/S1473309916000475>.

5 [89] Tadolini M, Lingsang RD, Tiberi S, et al. First case of extensively drug-resistant

6 tuberculosis treated with both delamanid and bedaquiline: TABLE 1. Eur. Respir. J.

7 [Internet]. 2016 [cited 2017 Jan 29];48:935–938. Available from:

8 <http://www.ncbi.nlm.nih.gov/pubmed/27288039>.

9 [90] Ahmad Z, Peloquin CA, Singh RP, et al. PA-824 exhibits time-dependent activity in a

10 murine model of tuberculosis. Antimicrob. Agents Chemother. [Internet]. 2011 [cited 2016

11 Jun 18];55:239–245. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20937781>.

12 [91] Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. Bactericidal activity of

13 pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.

14 Am. J. Respir. Crit. Care Med. [Internet]. 2015 [cited 2017 Jan 29];191:943–953. Available

15 from: <http://www.atsjournals.org/doi/10.1164/rccm.201410-1801OC>.

16 [92] Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-

17 824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet

18 (London, England) [Internet]. 2012 [cited 2017 Jan 29];380:986–993. Available from:

19 <http://linkinghub.elsevier.com/retrieve/pii/S0140673612610800>.

20 [93] Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line

21 antituberculosis drugs among patients treated for active tuberculosis. Am. J. Respir. Crit.

22 Care Med. [Internet]. 2003 [cited 2016 Jun 21];167:1472–1477. Available from:

23 <http://www.ncbi.nlm.nih.gov/pubmed/12569078>.

24 [94] Grosset J, Leventis S. Adverse effects of rifampin. Rev. Infect. Dis. [Internet]. [cited 2016

25 Jun 21];5 Suppl 3:S440-50. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/6356277>.

26 [95] Patel AM, McKeon J. Avoidance and management of adverse reactions to antituberculosis

1 drugs. *Drug Saf.* [Internet]. 1995 [cited 2016 Jun 21];12:1–25. Available from:

2 <http://www.ncbi.nlm.nih.gov/pubmed/7741981>.

3 [96] Long MW, Snider DE, Farer LS. U.S. Public Health Service Cooperative trial of three

4 rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. *Am. Rev. Respir. Dis.*

5 [Internet]. 1979 [cited 2016 Jun 24];119:879–894. Available from:

6 <http://www.ncbi.nlm.nih.gov/pubmed/110184>.

7 [97] Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and

8 pharmacodynamics of the rifamycin antibacterials. *Clin. Pharmacokinet.* [Internet]. 2001

9 [cited 2016 Jun 24];40:327–341. Available from:

10 <http://www.ncbi.nlm.nih.gov/pubmed/11432536>.

11 [98] Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of

12 antituberculosis therapy. *Am. J. Respir. Crit. Care Med.* [Internet]. 2006 [cited 2016 Jun

13 8];174:935–952. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17021358>.

14 [99] Poole G, Stradling P, Worlledge S. Potentially serious side effects of high-dose twice-weekly

15 rifampicin. *Br. Med. J.* [Internet]. 1971 [cited 2016 Jun 8];3:343–347. Available from:

16 <http://www.ncbi.nlm.nih.gov/pubmed/5314737>.

17 [100] Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-

18 weekly dosing for treatment of mycobacterial diseases. *Clin. Infect. Dis.* [Internet]. 2004

19 [cited 2016 Jun 24];38:1538–1544. Available from:

20 <http://www.ncbi.nlm.nih.gov/pubmed/15156439>.

21 [101] Worley M V, Estrada SJ, Estrada SJ. Bedaquiline: a novel antitubercular agent for the

22 treatment of multidrug-resistant tuberculosis. *Pharmacotherapy* [Internet]. 2014 [cited 2016

23 Jun 22];34:1187–1197. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25203970>.

24 [102] Chigutsa E, Visser ME, Swart EC, et al. The SLCO1B1 rs4149032 Polymorphism Is Highly

25 Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations:

26 Dosing Implications. *Antimicrob. Agents Chemother.* 2011;55:4122–4127.

- 1 [103] Zhang W, He Y-J, Gan Z, et al. OATP1B1 polymorphism is a major determinant of serum
2 bilirubin level but not associated with rifampicin-mediated bilirubin elevation. *Clin. Exp.*
3 *Pharmacol. Physiol.* [Internet]. 2007 [cited 2016 Jun 19];34:1240–1244. Available from:
4 <http://www.ncbi.nlm.nih.gov/pubmed/17973861>.
- 5 [104] Li L-M, Chen L, Deng G-H, et al. SLCO1B1 *15 haplotype is associated with rifampin-
6 induced liver injury. *Mol. Med. Rep.* [Internet]. 2012 [cited 2016 Jun 19];6:75–82. Available
7 from: <http://www.ncbi.nlm.nih.gov/pubmed/22562052>.
- 8 [105] Weiner M, Peloquin C, Burman W, et al. Effects of Tuberculosis, Race, and Human Gene
9 SLCO1B1 Polymorphisms on Rifampin Concentrations. *Antimicrob. Agents Chemother.*
10 [Internet]. 2010 [cited 2016 Jun 19];54:4192–4200. Available from:
11 <http://aac.asm.org/cgi/doi/10.1128/AAC.00353-10>.
- 12 [106] Song SH, Chang HE, Jun SH, et al. Relationship between CES2 genetic variations and
13 rifampicin metabolism. *J. Antimicrob. Chemother.* [Internet]. 2013 [cited 2016 Jun
14 24];68:1281–1284. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23471941>.
- 15 [107] Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single
16 nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP)
17 efflux transporters. *Int. J. Toxicol.* [Internet]. [cited 2016 Jun 22];25:231–259. Available
18 from: <http://www.ncbi.nlm.nih.gov/pubmed/16815813>.
- 19 [108] Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-
20 induced liver injury and early treatment failure in the 6-month four-drug standard treatment
21 of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. *Eur. J.*
22 *Clin. Pharmacol.* [Internet]. 2013 [cited 2016 Jun 17];69:1091–1101. Available from:
23 <http://www.ncbi.nlm.nih.gov/pubmed/23150149>.
- 24 [109] Fatiguso G, Allegra S, Calcagno A, et al. Ethambutol plasma and intracellular
25 pharmacokinetics: A pharmacogenetic study. *Int. J. Pharm.* [Internet]. 2016 [cited 2016 Jun
26 21];497:287–292. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26642947>.

- 1 [110] Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity:
2 concise up-to-date review. *J. Gastroenterol. Hepatol.* [Internet]. 2008 [cited 2016 Jun
3 22];23:192–202. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17995946>.
- 4 [111] Ramachandran G, Swaminathan S. Role of pharmacogenomics in the treatment of
5 tuberculosis: a review. *Pharmgenomics. Pers. Med.* [Internet]. 2012 [cited 2016 Jun 8];5:89–
6 98. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23226065>.
- 7 **•A review reporting available pharmacogenomic data on antituberculous drugs to**
8 **define the role of PG in TB treatment.**
- 9 [112] Lee S-W, Chung LS-C, Huang H-H, et al. NAT2 and CYP2E1 polymorphisms and
10 susceptibility to first-line anti-tuberculosis drug-induced hepatitis. *Int. J. Tuberc. Lung Dis.*
11 [Internet]. 2010 [cited 2016 Jun 24];14:622–626. Available from:
12 <http://www.ncbi.nlm.nih.gov/pubmed/20392357>.
- 13 [113] Gupta VH, Singh M, Amarapurkar DN, et al. Association of GST null genotypes with anti-
14 tuberculosis drug induced hepatotoxicity in Western Indian population. *Ann. Hepatol.*
15 [Internet]. [cited 2016 Jun 22];12:959–965. Available from:
16 <http://www.ncbi.nlm.nih.gov/pubmed/24114827>.
- 17 [114] Hiruy H, Rogers Z, Mbowane C, et al. Subtherapeutic concentrations of first-line anti-TB
18 drugs in South African children treated according to current guidelines: the PHATISA study.
19 *J. Antimicrob. Chemother.* [Internet]. 2015 [cited 2016 Jun 27];70:1115–1123. Available
20 from: <http://www.ncbi.nlm.nih.gov/pubmed/25505005>.
- 21 [115] Mukherjee A, Velpandian T, Singla M, et al. Pharmacokinetics of isoniazid, rifampicin,
22 pyrazinamide and ethambutol in Indian children. *BMC Infect. Dis.* [Internet]. 2015 [cited
23 2016 Feb 26];15:126. Available from:
24 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4373095&tool=pmcentrez&rend](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4373095&tool=pmcentrez&rendertype=abstract)
25 [ertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4373095&tool=pmcentrez&rendertype=abstract).
- 26 [116] Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance

- with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. *Eur. Respir. J.* [Internet]. 2014 [cited 2017 Jan 29];44:811–815. Available from: <http://erj.ersjournals.com/cgi/doi/10.1183/09031936.00060414>.
- [117] Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. *Clin. Infect. Dis.* [Internet]. 2010 [cited 2016 Jun 24];50:1288–1299. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20353364>.
- [118] Narendran G, Menon PA, Venkatesan P, et al. Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy. *Clin. Infect. Dis.* [Internet]. 2014 [cited 2016 Jun 24];59:1798–1804. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25156114>.
- [119] Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. *Antimicrob. Agents Chemother.* [Internet]. 2004 [cited 2016 Jun 24];48:4473–4475. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15504887>.
- [120] van Oosterhout JJ, Dzinjalama FK, Dimba A, et al. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. *Antimicrob. Agents Chemother.* [Internet]. 2015 [cited 2016 Jun 24];59:6175–6180. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26248378>.
- [121] Taburet A-M, Sauvageon H, Grinsztejn B, et al. Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy. *Clin. Infect. Dis.* [Internet]. 2015 [cited 2017 Jan 28];61:1328–1335. Available from: <https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/civ477>.
- [122] Ngaimisi E, Mugusi S, Minzi O, et al. Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis. *Clin. Pharmacol. Ther.* [Internet]. 2011 [cited 2017 Jan 28];90:406–413.

Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21814190>.

[123] Dickinson L, Winston A, Boffito M, et al. Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. *J. Antimicrob. Chemother.* [Internet]. 2016 [cited 2017 Jan 30];71:1041–1045. Available from: <https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkv439>.

[124] Jenny-Avital ER, Joseph K. Rifamycin-resistant *Mycobacterium tuberculosis* in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. *Clin. Infect. Dis.* [Internet]. 2009 [cited 2017 Jan 30];48:1471–1474. Available from: <https://academic.oup.com/cid/article-lookup/doi/10.1086/598336>.

[125] Weiner M, Egelund EF, Engle M, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. *J. Antimicrob. Chemother.* [Internet]. 2014 [cited 2017 Jan 29];69:1079–1085. Available from: <https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkt483>.

[126] Pandie M, Wiesner L, McIlleron H, et al. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. *J. Antimicrob. Chemother.* [Internet]. 2016 [cited 2017 Jan 29];71:1037–1040. Available from: <https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkv447>.

[127] Nijland HMJ, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. *Clin. Infect. Dis.* [Internet]. 2006 [cited 2016 Jun 22];43:848–854. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16941365>.

[128] Ruslami R, Nijland HMJ, Adhiarta IGN, et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. *Antimicrob. Agents Chemother.* [Internet]. 2010 [cited 2016 Jun 24];54:1068–1074. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20038625>.

- 1 [129] Requena-Méndez A, Davies G, Ardrey A, et al. Pharmacokinetics of rifampin in Peruvian
2 tuberculosis patients with and without comorbid diabetes or HIV. *Antimicrob. Agents*
3 *Chemother.* [Internet]. 2012 [cited 2016 Jun 24];56:2357–2363. Available from:
4 <http://www.ncbi.nlm.nih.gov/pubmed/22330931>.
- 5 [130] Kjellsson MC, Via LE, Goh A, et al. Pharmacokinetic evaluation of the penetration of
6 antituberculosis agents in rabbit pulmonary lesions. *Antimicrob. Agents Chemother.*
7 [Internet]. 2012 [cited 2016 Jun 8];56:446–457. Available from:
8 <http://www.ncbi.nlm.nih.gov/pubmed/21986820>.
- 9 [131] Prideaux B, Dartois V, Staab D, et al. High-sensitivity MALDI-MRM-MS imaging of
10 moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions.
11 *Anal. Chem.* [Internet]. 2011 [cited 2016 May 30];83:2112–2118. Available from:
12 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3158846&tool=pmcentrez&rend](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3158846&tool=pmcentrez&rendertype=abstract)
13 [ertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3158846&tool=pmcentrez&rendertype=abstract).
- 14 [132] Prideaux B, Via LE, Zimmerman MD, et al. The association between sterilizing activity and
15 drug distribution into tuberculosis lesions. *Nat. Med.* [Internet]. 2015 [cited 2016 Mar
16 13];21:1223–1227. Available from: <http://dx.doi.org/10.1038/nm.3937>.
- 17 [133] Iacobino A, Piccaro G, Giannoni F, et al. Activity of drugs against dormant *Mycobacterium*
18 tuberculosis. *Int. J. Mycobacteriology* [Internet]. 2016 [cited 2017 Jan 24];5:S94–S95.
19 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28043638>.
- 20 [134] Hartkoorn RC, Chandler B, Owen A, et al. Differential drug susceptibility of intracellular
21 and extracellular tuberculosis, and the impact of P-glycoprotein. *Tuberculosis (Edinb).*
22 [Internet]. 2007 [cited 2016 Jun 24];87:248–255. Available from:
23 <http://www.ncbi.nlm.nih.gov/pubmed/17258938>.
- 24 [135] Dhillon J, Mitchison DA. Activity and penetration of antituberculosis drugs in mouse
25 peritoneal macrophages infected with *Mycobacterium microti* OV254. *Antimicrob. Agents*
26 *Chemother.* [Internet]. 1989 [cited 2017 Jan 31];33:1255–1259. Available from:

1 <http://www.ncbi.nlm.nih.gov/pubmed/2802553>.

2 [136] Hand WL, Corwin RW, Steinberg TH, et al. Uptake of antibiotics by human alveolar
3 macrophages. *Am. Rev. Respir. Dis.* [Internet]. 1984 [cited 2016 Jun 24];129:933–937.
4 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/6732052>.

5 [137] Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.
6 *Nat. Rev. Microbiol.* [Internet]. 2014;12:159–167. Available from:
7 <http://www.ncbi.nlm.nih.gov/pubmed/24487820>.

8 **••This article provides a perspective insight on drug distribution in infected lung tissue**
9 **and in mycobacterial cells and how this technology could be used to design optimized**
10 **multidrug regimens.**

11 [138] Baietto L, Calcagno A, Motta I, et al. A UPLC-MS-MS method for the simultaneous
12 quantification of first-line antituberculars in plasma and in PBMCs. *J. Antimicrob.*
13 *Chemother.* [Internet]. 2015 [cited 2016 Feb 26];70:2572–2575. Available from:
14 <http://www.ncbi.nlm.nih.gov/pubmed/26066583>.

15 [139] Hartkoorn RC, Khoo S, Back DJ, et al. A rapid and sensitive HPLC-MS method for the
16 detection of plasma and cellular rifampicin. *J. Chromatogr. B. Analyt. Technol. Biomed. Life*
17 *Sci.* [Internet]. 2007 [cited 2016 Jun 24];857:76–82. Available from:
18 <http://www.ncbi.nlm.nih.gov/pubmed/17643357>.

19 [140] Motta I, Calcagno A, Baietto L, et al. Pharmacokinetics of first-line antitubercular drugs in
20 plasma and PBMCs. *Br. J. Clin. Pharmacol.* [Internet]. 2017 [cited 2017 Jan 29]; Available
21 from: <http://www.ncbi.nlm.nih.gov/pubmed/28097677>.

22 [141] Sarathy JP, Lee E, Dartois V. Polyamines inhibit porin-mediated fluoroquinolone uptake in
23 mycobacteria. *PLoS One* [Internet]. 2013 [cited 2016 Dec 19];8:e65806. Available from:
24 <http://www.ncbi.nlm.nih.gov/pubmed/23755283>.

25 [142] Holdiness MR. Clinical pharmacokinetics of clofazimine. A review. *Clin. Pharmacokinet.*
26 [Internet]. 1989 [cited 2017 Jan 31];16:74–85. Available from:

1 <http://www.ncbi.nlm.nih.gov/pubmed/2656045>.

2

	Rif	Rfb	<u>Rpt</u>	Inh	Etb	Pza	S
Dose	600 mg	300 mg	600 mg	300 mg	25 mg/kg	25-35 mg/kg	15 mg/kg
Binding protein [%]	88.6	71-85	98	10-15	10-30	10-40	34
Metabolism	Hepatic deacetylation, Autoinduction	Hepatic <u>deacetylation</u> , CYP3A	Hepatic <u>deacetylation</u>	Acetylation by NAT2	<u>10-15% hepatic, 50-55% eliminated</u>	Hepatic, 3% excreted unchanged	Eliminated 29-89% unchanged
Plasma half life [hours]	3-4	25-36	15	1.5 fast acetylators 4 slow acetylators	2-4	10	3
Parameter best predictive of activity[16]	AUC/MIC C _{max} /MIC C	AUC/MIC C _{max} /MIC	AUC/MIC C _{max} /MIC	AUC/MIC > C _{max} /MIC	AUC/MIC	AUC/MIC	AUC/MIC
Therapeutic range µg/ml[26]	8-24	0.3-0.9	8-30	3-6	2-6	20-60	35-45
Threshold associated with poor outcome[20]	AUC≤13 mg*h/l	AUC≤13 mg*h/l	N/A	AUC≤52 mg*h/l	N/A	AUC≤363 mg*h/l	N/A
I/P	2-5	N/A	N/A	1	10-20	<1[138]	<1

ratio[136]

--

1

2 **Table 1**

3 **Pharmacokinetic and pharmacodynamic properties of currently recommended antitubercular**
4 **drugs.**

5 (Rif, rifampicin; Rfb, rifabutin; **Rpt**, rifapentine; Inh, isoniazid; Etb, ethambutol; Pza,

6 pyrazinamide; S, streptomycin; AUC, Area Under the Curve; N/A, not assessed)

7

	Lfx	Mfx	Cs	PAS	Eto	Cfz	Lzd
Dose	500-1000 mg qd	400 mg	10-15 mg/kg	4 gr bid	15-20 mg/kg	100 mg	600 mg
Binding protein [%]	24-38	30-50	<20%	50-60	30	No data	31
Metabolism	Minimally hepatic	52% (N-sulfate and acyl glucuronide conjugates)	<u>65%</u> <u>excreted</u> <u>unchanged</u> <u>ed. 35%</u> <u>hepatic</u>	Hepatic via acetylation	Prodrug; Hepatic	<u>Hydrolytic dehalogenation, deamination, hydration and glucuronidation</u> [142]	Minimally hepatic via oxidation
Plasma half life	9 hrs	7 hrs	7-10 hrs	0.75-1	2-9 hrs	Up to 70 days	5-6 hrs
Parameter best predictive of activity[16]	AUC/MIC better than C _{max} /MIC	AUC/MIC better than C _{max} /MIC	N/A	N/A	N/A	N/A	T/MIC
Therapeutic range µg/ml	8-12[26]	3-5[26]	20-35[26]	20-60[26]	1-5[26]	0.5-4[26]	2-7

1

2 **Table 2**

3 **Pharmacokinetic and pharmacodynamic properties of principal second-line antitubercular**
4 **drugs.**

5 (Lfx, levofloxacin; Mfx, moxifloxacin; Cs, cycloserine; PAS, para-aminosalicylic acid; Eto,
6 ethionamide; Cfz, clofazimine; Lzd, linezolid; AUC, Area Under the Curve; N/A, not assessed)

	Bdq	Dlm	PA-824	
Dose	400 mg for 2 w then 200 mg 3x/w	100 mg bid	100 mg/200 mg	
Binding	99	99	95	6
protein [%]				7
Metabolism	Hepatic, via CYP3A4	Hepatic	Prodrug; hepatic	
Plasma half	24-30	30-38	16-20	9
life [hours]				10
Parameter	T/MIC	AUC/MC	T/MIC	
best				
predictive				
of				
activity[16]				
Therapeutic	N/A	N/A	N/A	14
range				15
µg/ml				16
				17

Table 3

Pharmacokinetic and pharmacodynamic properties of novel agents.

(Bdq, bedaquiline; Dlm, delamanid; PA-824, pretomanid; AUC, Area Under the Curve; N/A, not assessed)